Mothers against decapentaplegic homolog 3 (SMAD3) (SMAD3)

Mothers against decapentaplegic homolog 3 (SMAD3) is a key intracellular protein and transcription factor that serves as a central mediator in the canonical transforming growth factor-beta (TGF-β) signaling pathway [4][8]. Upon activation by TGF-β type I receptor kinases, SMAD3 is phosphorylated at its C-terminal SXS motif, allowing it to form a heteromeric complex with SMAD4 and translocate into the nucleus [1][10]. Once in the nucleus, the complex binds to SMAD-binding elements (SBEs) in the promoters of target genes to regulate diverse cellular processes such as cell growth, differentiation, apoptosis, and extracellular matrix production [7][9]. In disease contexts, SMAD3 is a major driver of tissue fibrosis and facilitates cancer metastasis through the induction of the epithelial-mesenchymal transition (EMT) [1][12]. Therapeutic strategies targeting this pathway focus on small molecule inhibitors of SMAD3 phosphorylation or DNA binding, as well as upstream TGF-β receptor inhibitors, to treat chronic fibrotic conditions and advanced malignancies [2][6].

Other names

SMAD family member 3Mothers against DPP homolog 3MADH3JV15-2HSPC193HsT17436MAD homolog 3

Inhibition of C-terminal phosphorylation, prevention of nuclear translocation, or disruption of the SMAD3-SMAD4 transcriptional complex and DNA binding [2][6][13].